eprosartan,
SK and F 108566,
SKF-108566,
Teveten,
EPROSARTAN MESYLATE,
144143-96-4,
Teveten,
eprosartan methanesulfonate,
Eprosartan (mesylate),
Eprosartan mesilate,
UNII-8N2L1NX8S3,
Eprosartan mesylate [USAN:BAN],
SK&F 108566-J,
8N2L1NX8S3,
CHEBI:48409,
SKF-108566J,
(E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid, monomethanesulfonate,
SK&F-108566-J,
DSSTox_CID_24217,
DSSTox_RID_80124,
DSSTox_GSID_44217,
Eprosartan mesylate dihydrate,
2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-, (E)-, monomethanesulfonate,
CAS-144143-96-4,
NCGC00164557-01,
Eprosartan Monomethanesulfonate,
Futuran,
Navixen,
Regulaten,
Tevetenz,
Epro-sartan mesylate dihydrate,
SR-05000001450,
MFCD08141807,
Teveten SB,
C23H24N2O4S.CH4O3S,
eprosartan-mesylate,
Teveten (TN),
AC1NR04M,
Eprosartan mesylate (USAN),
SCHEMBL41396,
sunitinib and its intermediate,
CHEMBL1200987,
DTXSID7044217,
AOB5517,
DJSLTDBPKHORNY-XMMWENQYSA-N,
HMS3262B17,
4-[[2-Butyl-5-(2-carboxy-3-thiophen-2-yl-prop-1-enyl)-imidazol-1-yl]methyl]benzoic acid mesylate,
Tox21_112186,
Tox21_500808,
HY-15834A,
s4102,
SK&F-108566J,
AKOS015994738,
Eprosartan mesylate, >=98% (HPLC),
Tox21_112186_1,
AM84399,
CCG-222112,
CS-2291,
KS-1233,
MP-0196,
SKF 108566,
NCGC00167505-02,
NCGC00261493-01,
AB0069224,
LS-173203,
ST2412854,
E-145,
E1161,
SW219286-1,
A13747,
D02082,
92605-EP2295430A2,
92605-EP2295431A2,
92605-EP2305670A1,
143E964,
A808180,
J-007923,
SR-05000001450-2,
Eprosartan mesylate, United States Pharmacopeia (USP) Reference Standard,
(|AE)-|A-[[2-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic Acid Monomethanesulfonate,
(E)-|A-[[2-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic Acid Methanesulfonate,
(E)-2-butyl-1-(p-carboxybenzyl)-alpha-2-thienylimidazole-5-acrylic acid monomethanesulfonate,
(E)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid compound with methanesulfonic acid (1:1),
(E)-alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-2-thiophenepropanoic acid monomethanesulfonate,
2-Thiophenepropanoic acid, alpha-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (alphaE)-, methanesulfonate (1:1),
4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate,
4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]-1-imidazolyl]methyl]benzoic acid; methanesulfonic acid,
4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid;methanesulfonic acid,
4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid;methanesulfonic acid.,
4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; methanesulfonic acid,
4-[[2-butyl-5-[(E)-3-oxidanyl-3-oxidanylidene-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; methanesulfonic acid,
Eprosartan mesylate|SK&F 108566|(?E)-?-[[2-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic acid methanesulfonate,
Eprosartan,
TEVETEN HCT,
cc-130,
CID5282474,
CS-O-01462,
SK&F-108566,
B1746,
C23-H24-N2-O4-S.C-H4-O3-S,
133040-01-4,